Streetbeat News

Earnings

UHT

Universal Health Realty (UHT) reported a decrease in Q4 adjusted earnings per share to $0.28, down from $0.41 YoY, while sales slightly increased to $24.32M from $24.13M YoY.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:57 pm

BGFV

Big 5 Sporting Goods (BGFV) anticipates a decrease in Q1 same-store sales in the low double-digit range and a net loss per basic share of $(0.30)-$(0.40), which is below the estimated $(0.15). The company attributes these trends to macroeconomic uncertainty and extreme weather affecting their sales.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:56 pm

IAS

IAS has projected its Q1 2024 revenue to be between $111M and $113M, which is below the estimated $119.7M.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:56 pm

ALC

Alcon projects its 2024 core diluted EPS to be between $3.00 and $3.10, compared to the estimated $3.04, and forecasts net sales to range from $9.9 billion to $10.1 billion, versus the estimated $9.95 billion.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:55 pm

ALC

Alcon (NYSE:ALC) reported Q4 2023 adjusted EPS of $0.70, surpassing the $0.67 estimate, but its sales of $2.33B fell short of the $2.34B estimate, marking an 8.21% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:54 pm

NRDY

Nerdy projects its Q1 revenue to be between $51M-$53M, falling short of the estimated $59.75M. For 2024, the revenue forecast is set between $232M-$246M, closely aligning with the estimate of $238.396M.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:52 pm

SP

SP Plus (NASDAQ:SP) reported Q4 2023 adjusted EPS of $0.60, missing the $0.85 estimate, and sales of $217.20M, below the $228.00M estimate. This represents a 5.23% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:50 pm

CPNG

Coupang, Inc. (NYSE:CPNG) reported Q4 results surpassing expectations with adjusted earnings of 8 cents per share against an estimate of 6 cents, and sales of $6.6 billion against an estimate of $6.44 billion. The company saw a 23.9% year-over-year sales increase and significant growth in its Product Commerce and Developing Offerings segments. CEO Bom Kim highlighted the growth in revenues, active customers, and WOW members, attributing it to the company's focus on customer satisfaction and value, especially through the WOW membership program.

Portfolio Pulse from Erica Kollmann

February 27, 2024 | 10:49 pm

CYTK

Cytokinetics projects 2024 revenue between $3M-$5M, with operating expenses of $420M-$450M and net cash utilization of $390M-$420M. After raising $83M through ATM equity and considering available long-term debt from Royalty Pharma, the company estimates a two-year cash runway.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:49 pm

MTUS

Metallus reported that its Q1 shipments are expected to be slightly lower than those in Q4 2023. This indicates a potential short-term decrease in operational output or sales.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:48 pm